Although the initial trial with dovitinib, a pan-tyrosine kinase inhibitor targeting FGFR, VEGFR, and other receptor tyrosine kinases, was discontinued due to serious side effects [30], our findings strongly support the continued exploration of FGFR inhibitors as therapeutic options for hemangioblastoma patients. Here, KDR is linked to hemangioblastoma.